Letter to Editor Regarding "bone Modifying Agents in Breast Cancer Patients As Adjuvant Therapy and Prevention of Cancer Treatment-induced Bone Loss (CTIBL): Evaluation of Risk of Medication-related Osteonecrosis of the Jaw (MRONJ)"

Overview

Journal Support Care Cancer

Specialties Critical Care
Oncology

Date 2024 Oct 1

PMID 39352599

Authors

Giuseppina Campisi

Alberto Bedogni

Giorgia Saia

Martina Coppini

Rodolfo Mauceri

Vittorio Fusco

Affiliations

Soon will be listed here.

References

Yarom N, Van Poznak C, Epstein J, Ottaviani G, Matsuda Y, Migliorati C . MASCC/ISOO Clinical Practice Statement: Adjuvant bone-modifying agents in primary breast cancer patients - prevention of medication-related osteonecrosis of the jaw. Support Care Cancer. 2024; 32(8):547. PMC: 11269502. DOI: 10.1007/s00520-024-08687-w. View

Eisen A, Somerfield M, Accordino M, Blanchette P, Clemons M, Dhesy-Thind S . Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update. J Clin Oncol. 2022; 40(7):787-800. DOI: 10.1200/JCO.21.02647. View

Coleman R, Hadji P, Body J, Santini D, Chow E, Terpos E . Bone health in cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2020; 31(12):1650-1663. DOI: 10.1016/j.annonc.2020.07.019. View

Bedogni A, Mauceri R, Fusco V, Bertoldo F, Bettini G, Di Fede O . Italian position paper (SIPMO-SICMF) on medication-related osteonecrosis of the jaw (MRONJ). Oral Dis. 2024; 30(6):3679-3709. DOI: 10.1111/odi.14887. View

Drudge-Coates L, van Muilekom E, de la Torre-Montero J, Leonard K, van Oostwaard M, Niepel D . Management of bone health in patients with cancer: a survey of specialist nurses. Support Care Cancer. 2019; 28(3):1151-1162. PMC: 6989658. DOI: 10.1007/s00520-019-04858-2. View

Valsecchi A, Fusco V, Di Maio M, Santini D, Tucci M, De Giorgi U . Management of cancer treatment-induced bone loss in patients with breast and hormone sensitive prostate cancer: AIOM survey. Tumori. 2024; 110(3):174-185. DOI: 10.1177/03008916241236279. View

Price N, Lipton A, Jain V, Ruggiero S . Prevention and management of osteonecrosis of the jaw associated with bisphosphonate therapy. Support Cancer Ther. 2008; 2(1):14-7. DOI: 10.1016/s1543-2912(13)60101-0. View

Lorenzo-Pouso A, Perez-Sayans M, Chamorro-Petronacci C, Gandara-Vila P, Lopez-Jornet P, Carballo J . Association between periodontitis and medication-related osteonecrosis of the jaw: A systematic review and meta-analysis. J Oral Pathol Med. 2019; 49(3):190-200. DOI: 10.1111/jop.12963. View

Allen M, Kubek D, Burr D, Ruggiero S, Chu T . Compromised osseous healing of dental extraction sites in zoledronic acid-treated dogs. Osteoporos Int. 2010; 22(2):693-702. PMC: 2999646. DOI: 10.1007/s00198-010-1268-4. View

10.

Nicolatou-Galitis O, Papadopoulou E, Vardas E, Kouri M, Galiti D, Galitis E . Alveolar bone histological necrosis observed prior to extractions in patients, who received bone-targeting agents. Oral Dis. 2020; 26(5):955-966. DOI: 10.1111/odi.13294. View

11.

Kwoen M, Park J, Kim K, Lee J, Kim J, Lee H . Association between periodontal disease, tooth extraction, and medication-related osteonecrosis of the jaw in women receiving bisphosphonates: A national cohort-based study. J Periodontol. 2022; 94(1):98-107. DOI: 10.1002/JPER.21-0611. View

12.

Mauceri R, Coniglio R, Abbinante A, Carcieri P, Tomassi D, Panzarella V . The preventive care of medication-related osteonecrosis of the jaw (MRONJ): a position paper by Italian experts for dental hygienists. Support Care Cancer. 2022; 30(8):6429-6440. PMC: 9213300. DOI: 10.1007/s00520-022-06940-8. View